Home India Ministry of Health and Family Welfare Whereas a draft of certain rules further to amend the Drugs ...
Date: 2019-11-06 Category: Extra Ordinary State: Union Government Country: India

Whereas a draft of certain rules further to amend the Drugs and Cosmetics Rules, 1945,

Issued by Ministry of Health and Family Welfare · Department of Health and Family Welfare

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

Executive Summary: This notification announces amendments to the Drugs and Cosmetics Rules, 1945, effective from the date of publication in the Official Gazette. It introduces requirements for drug manufacturers regarding brand names or trade names, mandating an undertaking to ensure no confusion or duplication exists. It also introduces Form 51, related to these requirements. Key Points / Main Content: Brand Name/Trade Name Undertaking: * Applicants intending to market a drug under a specific brand name or trade name must furnish an undertaking in Form 51 to the licensing authority. * The undertaking confirms that, based on due diligence (trademark registry, central database, literature, and internet searches), the proposed name does not already exist for another drug in the country. * The undertaking also confirms that the proposed name will not cause confusion or deception in the market. Rule Amendments: * Rule 71: After sub-rule 8, a new sub-rule 9 is inserted, requiring the brand name/trade name undertaking. * Rule 71A: After sub-rule 4, a new sub-rule 5 is inserted, requiring the brand name/trade name undertaking. * Rule 71B: After clause iv, a new clause v is inserted, requiring the brand name/trade name undertaking. * Rule 76: After sub-rule 10, a new sub-rule 11 is inserted, requiring the brand name/trade name undertaking. * Rule 76A: After clause iv, a new clause v is inserted, requiring the brand name/trade name undertaking. Form 51: * A new Form 51 is introduced, titled "Form of undertaking to the licensing authority for marketing a drug under a brand name or trade name." * The form requires the applicant to specify the drug name, dosage form, and composition. * It includes the undertaking regarding brand name/trade name originality and non-confusion. Impact Analysis: Drug Manufacturers/Applicants: * Impact: They must now conduct due diligence regarding brand names/trade names and provide a formal undertaking (Form 51) to the licensing authority. * Action Required: Implement procedures for trademark searches, database checks, and literature reviews to ensure brand name originality. Complete and submit Form 51 with their applications. Licensing Authorities: * Impact: They are now responsible for receiving and reviewing the brand name/trade name undertakings (Form 51) from drug manufacturers/applicants. * Action Required: Update application review processes to include verification of Form 51 and the information provided within it.

Key Entities Referenced

Drugs and Cosmetics Rules, 1945: A set of rules governing the import, manufacture, distribution, and sale of drugs and cosmetics in India. This notification introduces amendments to these rules. Drugs and Cosmetics Act, 1940: An act of the Indian Parliament that regulates the import, manufacture, distribution and sale of drugs and cosmetics. This act is the basis for the Drugs and Cosmetics Rules, 1945. Ministry of Health and Family Welfare: A ministry in the Government of India responsible for health policy and family welfare. New Delhi: The capital of India and the location where the notification was issued. Central Drugs Standard Control Organisation: The national regulatory authority in India responsible for the regulation of pharmaceuticals and medical devices. Drugs Technical Advisory Board: A statutory body under the Drugs and Cosmetics Act, 1940 that advises the Central Government on technical matters related to drugs and cosmetics. Drugs and Cosmetics Thirteenth Amendment Rules, 2019: The name given to the set of amendments introduced to the Drugs and Cosmetics Rules, 1945, by this notification. Form 51: A form of undertaking to the licensing authority for marketing a drug under a brand name or trade name.
Official Source Record View Original Source →
See Full Document Text
jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II—[k.M 3—mi&[k.M (i) PART II—Section 3—Sub-section (i) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 651] ubZ fnYyh] cq/okj] uoEcj 6] 2019@dkfrZd 15] 1941 No. 651] NEW DELHI, WEDNESDAY, NOVEMBER 6, 2019/KARTIKA 15, 1941 (cid:1)(cid:1)(cid:1)(cid:1)वव वव ाााा(cid:1)(cid:1)(cid:1)(cid:1) (cid:5)(cid:5) (cid:5) (cid:5)यय यय एएएएवववव ंं ंंपपपप(cid:10)(cid:10)(cid:10)(cid:10)ररररववववाााारररर कककक(cid:13)(cid:13)(cid:13)(cid:13)यय यय ााााणणणण मममम(cid:16)(cid:16)ंं(cid:16)(cid:16)ंं ााााललललयययय (((((cid:1)(cid:1)(cid:1)(cid:1)वव वव ाााा(cid:1)(cid:1)(cid:1)(cid:1)(cid:5)(cid:5) (cid:5)(cid:5) यय यय एएएएवववव ंं ंंपपपप(cid:10)(cid:10)(cid:10)(cid:10)ररररववववाााारररर कककक(cid:13)(cid:13)(cid:13)(cid:13)यय यय ााााणणणण ििििववववभभभभाााागगगग)))) अअअअििििधधधधससससचचूूचचूू ननननाााा नई (cid:4)द(cid:6) ली, 6 नव(cid:10) बर, 2019 ससससाााा....ककककाााा....ििििनननन.... 888822228888((((अअअअ))))....—ओषिध और (cid:18)साधन साम(cid:22)ी िनयम, 1945 का और संशोधन करने के िलए कितपय िनयम का (cid:18)ा!प, ओषिध और (cid:18)साधन साम(cid:22)ी अिधिनयम, 1940 (1940 का 23) क# धारा 12 क# उप-धारा (1) और धारा 33 क# उप-धारा (1) अधीन यथा अपिे &त, भारत सरकार के ( वा( ) य और प*रवार क(cid:6) याण मं,ालय (( वा( ) य और प*रवार क(cid:6) याण िवभाग) क# अिधसूचना स.ं सा.का.िन. 152(अ), तारीख 26 फरवरी, 2019 /ारा भारत के राजप,, असाधारण, भाग II, खंड 3, उप-खंड (i) म 1 (cid:18)कािशत (cid:4)कया गया था, िजसम 1उन सभी 3 यि4य स,े िजनके उसस े (cid:18)भािवत होन े क# सभं ावना ह ैउस तारीख स,े िजसको उ7त अिधसूचना अ8त9व:; करने वाली राजप, क# (cid:18)ितयां जनता को उपल< ध करा दी गई थ=, प>तालीस (cid:4)दन क# अविध के अवसान स ेपहले आ&ेप और सझु ाव आंमि,त (cid:4)कए गए थ;े और उ4 राजप, क# (cid:18)ितया ं27 फरवरी, 2019 को जनता को उपल<ध करा दी गई थ=; और उ7त िनयम पर जनता से (cid:18)ाB आ&पे और सझु ाव पर के8C ीय सरकार /ारा िवचार कर िलया गया ह;ै अत: अब, केनC ् ीय सरकार, ओषिध और (cid:18)साधन साम(cid:22)ी अिधिनयम, 1940 (1940 का 23) क# धारा 12 और धारा 33 /ारा (cid:18)दLत शि4य का (cid:18)योग करते Mए, ओषिध तकनीक# सलाहकार बोड :स ेपरामश: करन ेके पO चात,् ओषिध और (cid:18)साधन साम(cid:22)ी िनयम, 1945 का और सशं ोधन करन ेके िलए िन(cid:10) निलिखत िनयम बनाती ह,ै अथा:त:्― 1. (1) इन िनयम का संि&B नाम ओषिध और (cid:18)साधन साम(cid:22)ी (तेरहवा ंसंशोधन) िनयम, 2019 ह।ै (2) य ेराजप, म1 उनके (cid:18)काशन क# तारीख को (cid:18)वृत ह ग।े 2. ओषिध और (cid:18)साधन साम(cid:22)ी िनयम, 1945 (िजसे इसम1 इसके पTात् उ4 िनयम कहा गया ह)ै के िनयम 71 के, उपिनयम (8) के पOच ात् िनUिलिखत उपिनयम अतं ः(थािपत (cid:4)कया जाएगा, अथा:त:्― “(9) य(cid:4)द आवेदक Xांड नाम या Yावसियक नाम के अधीन ओषिध िवपणन करने का आशय रखता ह,ै आवेदक को Yापार िच8ह रिज(Zी, क1Cीय ओषिध मानक िनयं,ण संगठन /ारा रखे गए Xाडं नाम या Yावसाियक 5757 GI/2019 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] नाम के िलए क1Cीय आकं ड़ा सचं य, भारत म 1िविन9मत: ओषिध के <यौर पर सािहLय और स8दभ: पु(तक और इंटरनेट म1 जाँच पड़ताल के आधार पर अपन े सव‘aम bान पर उसी भाव का एक वचनबंध (cid:18)!प 51 पर अनुbापन (cid:18)ािधकारी को (cid:18)(तुत करेगा (cid:4)क इस (cid:18)कार का या समान Xाडं नाम या Yावसाियक नाम दशे म1 (cid:4)कसी ओषिध के संबंध म 1 पहल े स े िवcमान नह= ह ै और (cid:18)(तािवत Xांड नाम या Yावसाियक नाम से िवपणन म1 कोई dम या धोखा नह= होगा ।”। 3. उ7त िनयम म1, िनयम 71क के उपिनयम (4) के पTात,् परंतकु स े पहल े िनUिलिखत उपिनयम अतं ः(थािपत (cid:4)कया जाएगा, अथा:त:्― “(5) य(cid:4)द आवेदक Xांड नाम या Yावसाियक नाम के अधीन ओषिध िवपणन करन े का आशय रखता ह,ै आवेदक को Yापार िच8ह रिज(Zी, क1Cीय ओषिध मानक िनयं,ण संगठन /ारा रख े गए Xाडं नाम या Yावसियक नाम के िलए क1Cीय आंकड़ा सचं य, भारत म1 िविन9म:त ओषिध के <यौर पर सािहLय और स8दभ: पु(तक और इंटरनेट म1 जाँच पड़ताल के आधार पर अपने सव‘aम bान पर उसी भाव का एक वचनबंध (cid:18)!प 51 पर अनुbापन (cid:18)ािधकारी को (cid:18)(तुत करेगा (cid:4)क इस (cid:18)कार का या समान Xांड नाम या Yावसाियक नाम दशे म 1 (cid:4)कसी ओषिध के संबंध म1 पहल े से िवcमान नह= ह ै और (cid:18)(तािवत Xांड नाम या Yावसाियक नाम से िवपणन म 1 कोई dम या धोखा नह= होगा ।”। 4. उ7त िनयम म,1 िनयम 71ख के खंड (iv) के पTात,् परंतुक स ेपहले िनUिलिखत उपिनयम अतं ः(थािपत (cid:4)कया जाएगा, अथा:त्:― “(v) य(cid:4)द आवेदक Xांड नाम या Yावसाियक नाम के अधीन ओषिध िवपणन करने का आशय रखता ह,ै आवेदक को Yापार िच8ह रिज(Zी, क1Cीय ओषिध मानक िनयं,ण संगठन /ारा रखे गए Xाडं नाम या Yावसाियक नाम के िलए क1Cीय आंकड़ा संचय, भारत म1 िविन9मत: ओषिध के <यौर पर सािहLय और स8दभ :पु(तक और इंटरनेट म1 जाँच पड़ताल के आधार पर अपने सव‘aम bान पर उसी भाव का एक वचनबंध (cid:18)!प 51 पर अनुbापन (cid:18)ािधकारी को (cid:18)(तुत करेगा (cid:4)क इस (cid:18)कार का या समान Xांड नाम या Yावसाियक नाम दशे म 1 (cid:4)कसी ओषिध के संबंध म1 पहल े से िवcमान नह= ह ै और (cid:18)(तािवत Xांड नाम या Yावसाियक नाम से िवपणन म 1 कोई dम या धोखा नह= होगा ।”। 5. उ7त िनयम म,1 िनयम 76 के उपिनयम (10) के पTात,् िनUिलिखत उपिनयम अतं ः(थािपत (cid:4)कया जाएगा, अथा:त:्― “(11) य(cid:4)द आवेदक Xांड नाम या Yावसाियक नाम के अधीन ओषिध िवपणन करन े का आशय रखता ह,ै आवेदक को Yापार िच8ह रिज(Zी, क1Cीय ओषिध मानक िनयं,ण संगठन /ारा रखे गए Xाडं नाम या Yावसाियक नाम के िलए क1Cीय आंकड़ा संचय, भारत म1 िविन9म:त ओषिध के <यौर पर सािहLय और स8दभ: पु(तक और इंटरनेट म1 जाँच पड़ताल के आधार पर अपने सव‘aम bान पर उसी भाव का एक वचनबंध (cid:18)!प 51 पर अनुbापन (cid:18)ािधकारी को (cid:18)(तुत करेगा (cid:4)क इस (cid:18)कार का या समान Xांड नाम या Yावसाियक नाम दशे म 1 (cid:4)कसी ओषिध के संबंध म1 पहल े से िवcमान नह= ह ै और (cid:18)(तािवत Xांड नाम या Yावसाियक नाम से िवपणन म 1 कोई dम या धोखा नह= होगा ।”। 6. उ7त िनयम म1, िनयम 76क के के खंड (iv) के पTात,् परंतुक स े पहल े िनUिलिखत उपिनयम अंतः(थािपत (cid:4)कया जाएगा, अथा:त:्― “(v) य(cid:4)द आवेदक Xांड नाम या Yावसाियक नाम के अधीन ओषिध िवपणन करने का आशय रखता ह,ै आवेदक को Yापार िच8ह रिज(Zी, क1Cीय ओषिध मानक िनयं,ण संगठन /ारा रखे गए Xाडं नाम या Yावसाियक नाम के िलए क1Cीय आंकड़ा संचय, भारत म1 िविन9म:त ओषिध के <यौर पर सािहLय और स8दभ: पु(तक और इंटरनेट म1 जाँच पड़ताल के आधार पर अपने सव‘aम bान पर उसी भाव का एक वचनबंध (cid:18)!प 51 पर अनुbापन (cid:18)ािधकारी को (cid:18)(तुत करेगा (cid:4)क इस (cid:18)कार का या समान Xांड नाम या Yावसाियक नाम दशे म 1 (cid:4)कसी ओषिध के संबंध म1 पहल े से िवcमान नह= ह ै और (cid:18)(तािवत Xांड नाम या Yावसाियक नाम से िवपणन म 1 कोई dम या धोखा नह= होगा ।”।¹Hkkx IIµ[k.M 3(i)º Hkkjr dk jkti=k % vlk/kj.k 3 7. उ7त िनयम म,1 अनसु ूची क म,1 (cid:18)!प 50 के पTात,् िनUिलिखत (cid:18)!प अंतः(थािपत (cid:4)कया जाएगा, अथात: :्― ““““(cid:18)(cid:18)(cid:18)(cid:18)(cid:19)(cid:19)(cid:19)(cid:19)पपपप 55551111 [िनयम 71(9), 71क(5), 71ख(v), 76(11) और 76क(v) दिे खए] (cid:4)कसी Xांड नाम या Yावसाियक नाम के अधीन (cid:4)कसी ओषिध के िवपणन के िलए अनुbापन (cid:18)ािधकारी को वचनबंध का (cid:18)!प (1) म> …………………….. का ……………….. Xांड नाम या Yावसाियक नाम ………... के अधीन िनच ेिविनeद;: ओषिध िवपणन करन ेका आशय रखता f ँ (i) ओषिध का नाम (ii) खुराक (cid:18)!प (iii) संरचना (2) म>, Yापर िच8ह रिज(Zी, क1Cीय ओषिध मानक िनयं,ण संगठन /ारा रखे गए Xांड नाम या Yावसाियक नाम के िलए क1Cीय आकं ड़ा संचय, भारत म 1िविन9म:त ओषिध के <यौर पर सािहLय और संदभ: पु(तक और इंटरनेट म 1जाँच पड़ताल के आधार पर अपन ेसव‘aम bान पर, यह वचनबंध करता f ँक# इस (cid:18)कार का या समान Xांड नाम या Yावसाियक नाम देश म 1 (cid:4)कसी ओषिध के संबंध म1 पहले स े िवcमान नह= ह ै और (cid:18)(तािवत Xाडं नाम या Yावसाियक नाम स ेिवपणन म1 कोई dम या धोखा नह= होगा। (थान ………… तारीख ………. (िविनमा:ता या िविनमा:ता क# ओर स े ह(ता&र, नाम पदनाम मुहर/मCु ा) ।”। [फा. सं. ए7 स. 11018/48/2018–डीआरएस] डॉ. मनदीप के. भiडारी, संयु7त सिचव (cid:10)(cid:10)(cid:10)(cid:10)टटटट(cid:21)(cid:21)(cid:21)(cid:21)पप पप णणणण :::: मूल िनयम अिधसूचना संjय ा फा. 28-10/45-एच (1), तारीख 21 (cid:4)दस(cid:10) बर, 1945 /ारा भारत के राजप, म 1 (cid:18)कािशत (cid:4)कए गए थे और अिधसूचना सjं या सा.का.िन. 653(अ), तारीख 13 िसतंबर, 2019 /ारा अंितम बार संशोिधत (cid:4)कए गए थ।े MINISTRY OF HEALTH AND FAMILY WELFARE (Department of Health and Family Welfare) NOTIFICATION New Delhi, the 6th November, 2019 G.S.R. 828(E).—Whereas a draft of certain rules further to amend the Drugs and Cosmetics Rules, 1945, was published as required under sub-section (1) of section 12 and sub-section (1) of section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940) vide notification of the Government of India in the Ministry of Health and Family Welfare (Department of Health and Family Welfare) number G.S.R. 152(E), dated the 26th February, 2019, in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), inviting objections and suggestions from persons likely to be affected thereby before the expiry of a period of forty-five days from the date on which the copies of the Official Gazette containing the said notification were made available to the public;4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] And whereas copies of said Official Gazette were made available to the public on the 27th February, 2019; And whereas objections and suggestions received from the public on the said rules have been considered by the Central Government; Now, therefore, in exercise of the powers conferred under sections 12 and 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government, after consultation with the Drugs Technical Advisory Board, hereby makes the following rules further to amend the Drugs and Cosmetics Rules, 1945, namely:― 1. (1) These rules may be called the Drugs and Cosmetics (Thirteenth Amendment) Rules, 2019. (2) They shall come into force on the date of their publication in the Official Gazette. 2. In the Drugs and Cosmetics Rules, 1945 (hereinafter referred to as said rules), in rule 71, after sub- rule (8), the following sub-rule shall be inserted, namely:― “(9) In case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation, literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market.”. 3. In the said rules, in rule 71A, after sub-rule (4), before the proviso, the following sub-rule shall be inserted, namely:― “(5) In case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation, literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market.”. 4. In the said rules, in rule 71B, after clause (iv), before the proviso, the following clause shall be inserted, namely:― “(v) in case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation, literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market:”. 5. In the said rules, in rule 76, after sub-rule (10), the following sub-rule shall be inserted, namely:― “(11) In case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation, literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market.”. 6. In the said rules, in rule 76A, after clause (iv), before the proviso, the following clause shall be inserted, namely:― “(v) in case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of¹Hkkx IIµ[k.M 3(i)º Hkkjr dk jkti=k % vlk/kj.k 5 drugs maintained by Central Drugs Standard Control Organisation, literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market:”. 7. In the said rules, in Schedule A, after Form 50, the following Form shall be inserted, namely:― “FORM 51 [See rules 71(9), 71A(5), 71B(v), 76(11) and 76A(v)] Form of undertaking to the licensing authority for marketing a drug under a brand name or trade name (1) I .............................. of............................. intend to market the drug specified below under a brand name or trade name - …………………………… (i) Name of the drug : (ii) Dosage form : (iii) Composition : (2) I hereby give this undertaking that to the best of my knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation, literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market. Place……………….. Date ……….............. [Signature, Name, Designation Seal/Stamp of manufacturer or on behalf of the manufacturer].”. [F. No. X.11018/48/2018-DRS] Dr. MANDEEP K. BHANDARI, Jt. Secy. Note: The principal rules were published in the Official Gazette vide notification No. F.28-10/45-H (1) dated 21st December, 1945 and last amended vide notification number G.S.R. 653(E), dated the 13th September, 2019. Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.

Continue your research